InSite Vision (INSV) Stock Price, News & Analysis

Company Overview

InSite Vision, Inc. (OTCMKTS:INSV) is a biotechnology company focused on the development and commercialization of innovative therapies for gastrointestinal and mucosal health. The company’s principal activity centers on advancing its proprietary antibiotic formulation, Aemcolo® (rifamycin SV), which is indicated for the treatment of travelers’ diarrhea in adult patients. Utilizing targeted delivery technology, InSite Vision aims to maximize therapeutic efficacy at the site of infection while minimizing systemic exposure.

Founded in the late 1980s and headquartered in Fort Lauderdale, Florida, InSite Vision has evolved from a research-driven enterprise into a commercial-stage company. The firm’s research and development efforts emphasize oral, minimally absorbed compounds engineered to address infectious diseases in the gastrointestinal tract. Beyond its lead product, the company maintains a pipeline of formulation technologies designed to refine absorption profiles, dosing regimens and patient compliance in both acute and chronic indications.

InSite Vision serves domestic and select international markets through its specialized distribution network. The company has forged strategic partnerships with contract manufacturing organizations and global licensing partners to facilitate efficient product supply and marketing support. By leveraging established regulatory pathways, InSite Vision has secured FDA approval for Aemcolo® and continues to pursue additional indications and geographies where travelers’ diarrhea remains a significant public health concern.

Leadership at InSite Vision comprises seasoned executives with expertise in biopharmaceutical development, regulatory affairs and commercial strategy. The company’s executive team draws on decades of experience in antibiotic innovation and global product launches. Under this direction, InSite Vision remains committed to delivering novel, site-specific therapies that address unmet medical needs and enhance patient outcomes in the field of gastrointestinal health.

Key Stats

• Today's Range: N/A
• 50-Day Range: N/A
• 52-Week Range: N/A
• Volume: N/A
• Average Volume: 650,138 shs
• Market Capitalization: N/A
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

INSV Stock Analysis - Frequently Asked Questions

How do I buy shares of InSite Vision?

Shares of INSV stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of InSite Vision own?

Based on aggregate information from My MarketBeat watchlists, some other companies that InSite Vision investors own include Aralez Pharmaceuticals (ARLZ), Novelion Therapeutics (NVLN), Portola Pharmaceuticals (PTLA), Porsche Automobil (POAHY), MannKind (MNKD), Liquidia Technologies (LQDA) and iBio (IBIO).

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Manufacturing
• Industry: Pharmaceutical Preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: OTCMKTS:INSV
• CIK: 802724
• Web: www.insitevision.com
• Phone: +1-510-8658800
• Fax: N/A
• Employees: N/A
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: N/A
• Free Float: N/A
• Market Cap: N/A
• Optionable: Not Optionable
• Beta: N/A